IP Library › Granted Patent US 9,867,864
Granted Patent B2
US 9,867,864 · App. 15/064,099 · Granted Jan 16, 2018

Use of somatostatin analogs in control of hypoglycemia

Inventor: Herbert Schmid (Neuenburg, DE)
Assignee: Novartis AG
A61K38/12A61K38/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,867,864
App. No.
15/064,099
Granted
Jan 16, 2018
Kind
B2
Abstract

The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the control of hypoglycemia.

Claims (1)

1. A method of treating post-prandial reactive hypoglycemia consisting of administering to a patient in need thereof pasireotide or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2020
From: NOVARTIS AG
To: RECORDATI AG
Reel/Frame 051945/0630 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: SCHMID, HERBERT
To: NOVARTIS AG
Reel/Frame 051821/0603 →
Priority Claims (1)
EP 08159918 · Jul 8, 2008 · regional
Continuity (2)
Continuation 13002828
Related Publication 20160184388A1 · Jun 30, 2016